Register Login

Olema Oncology (OLMA)

(90% Positive) Olema Oncology (OLMA) Announces Enrollment Update for opportunity Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:55 p.m.

    📋 Olema Oncology (OLMA) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 16:44:46

    Event Type: Clinical Trial Update

    Event Details:

    Olema Oncology (OLMA) Announces Clinical Trial Update Olema Oncology (OLMA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: opportunity, indications
    • Diseases/Conditions: palazestrant
    • Clinical Stage: clinical trial
    • Updated Timeline: December 31, 2025, January 2025
      • targeting the right patients, with the right properties, with the right combo partner, palazestrant has the potential to succeed in 1L MBC NOW ENROLLING 2028
      • expected in Fall 2026
      • Anticipated initial monotherapy and combination data from the Phase 1 study 2/3L = second/third-line; ER+ = estrogen receptor positive; KAT6 = lysine acetyltransferase 6; HER2- = human epidermal growth factor receptor 2 negative; MBC = metastatic breast cancer OP-3136

    🔬 Clinical Development Pipeline (Olema Oncology):

    Product Type Development Stage Therapeutic Area Source
    Blood Draw PROCEDURE Preclinical Breast Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Olema Oncology
    • Ticker Symbol: OLMA

Search

News categories